or Try an Advanced Search...

    Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    C 11.14 2.96% 0.32
    OLMA closed up 2.96 percent on Monday, July 1, 2024, on 68 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Down
    Historical OLMA trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Support Bullish 2.96%
    Wide Bands Range Expansion 2.96%
    Oversold Stochastic Weakness 2.96%
    Wide Bands Range Expansion -0.62%
    Older End-of-Day Signals for OLMA ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 4 hours ago
    Up 3% about 5 hours ago
    Possible Inside Day about 6 hours ago
    Up 2% about 7 hours ago
    Up 1% about 7 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    OLMA Chart by TradingView
    Basic chart:

    Profile

    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Hormones Epidermal Growth Factor Receptor Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant

    Is OLMA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 17 Olema Pharmaceuticals: Still Merits A Small Holding
    Jun 14 TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors
    Jun 4 Pfizer data for breast cancer therapy sends Olema higher
    May 28 Olema Oncology to Participate in Upcoming Investor Conferences in June
    May 24 Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans
    May 15 Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
    May 9 Olema Pharmaceuticals GAAP EPS of -$0.56 beats by $0.02
    May 8 Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
    May 8 Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
    May 1 Olema Oncology to Participate in Upcoming Investor Conferences in May
    See more OLMA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.7911
    52 Week Low 7.78
    Average Volume 1,049,045
    200-Day Moving Average 12.39
    50-Day Moving Average 10.84
    20-Day Moving Average 12.29
    10-Day Moving Average 11.48
    Average True Range 0.85
    RSI (14) 46.81
    ADX 19.73
    +DI 20.57
    -DI 20.77
    Chandelier Exit (Long, 3 ATRs) 12.81
    Chandelier Exit (Short, 3 ATRs) 11.89
    Upper Bollinger Bands 14.25
    Lower Bollinger Band 10.32
    Percent B (%b) 0.21
    BandWidth 32.05
    MACD Line 0.04
    MACD Signal Line 0.27
    MACD Histogram -0.227
    Fundamentals Value
    Market Cap 613.78 Million
    Num Shares 55.1 Million
    EPS -2.31
    Price-to-Earnings (P/E) Ratio -4.82
    Price-to-Sales 0.00
    Price-to-Book 3.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.30
    Resistance 3 (R3) 12.24 11.81 12.10
    Resistance 2 (R2) 11.81 11.51 11.83 12.04
    Resistance 1 (R1) 11.47 11.33 11.64 11.53 11.97
    Pivot Point 11.04 11.04 11.12 11.06 11.04
    Support 1 (S1) 10.70 10.74 10.87 10.76 10.31
    Support 2 (S2) 10.27 10.56 10.29 10.24
    Support 3 (S3) 9.93 10.27 10.18
    Support 4 (S4) 9.99